Free Shipping Worldwide

Secure Payment

Chinese Patent ZL 202180032661.0 certificate for beta-glucan detection and quantification, Toei Shinyaku

Toei Shinyaku Granted Chinese Patent for Beta-Glucan Detection and Quantification Technology – Now Patented in Japan, the U.S. and China

Posted on October 28 2026, By: MotoiAkitomo

Chinese Patent ZL 202180032661.0 certificate for beta-glucan detection and quantification, Toei Shinyaku

Toei Shinyaku Co., Ltd. has been granted a Chinese patent (ZL 202180032661.0) for a method and kit for detecting and quantifying beta-1,6-branched beta-1,3-glucan and beta-1,3-glucan. The patent took effect upon publication of the grant on October 9, 2026.

The technology was developed through joint research on King Agaricus KA21 (outdoor-cultivated Agaricus brasiliensis KA21) with the Department of Immunology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences. Following registration in Japan (February 2025) and the United States (September 2026), it is now patented in three countries: Japan, the U.S. and China.

Patent Details

  • Chinese Patent No.: ZL 202180032661.0
  • Grant publication No.: CN 115516112 B
  • Grant publication date (effective date): October 9, 2026
  • Title: Method for detecting and quantifying beta-1,6-branched beta-1,3-glucan or beta-1,3-glucan, and kit for detecting and quantifying the same
  • Patent holder: Toei Shinyaku Co., Ltd.
  • Inventors: Daisuke Yamanaka, Yoshiyuki Adachi
  • Filing date: September 1, 2021 (PCT/JP2021/032154; priority date September 7, 2020)
  • Expiration: August 31, 2041
  • Corresponding patents: JP 7632898 (registered February 10, 2025) / US 12,736,534 B2 (issued September 15, 2026)

About the Technology

Beta-glucans are the main components of mushrooms such as Agaricus, and their properties differ depending on how they are linked and branched. This technology uses a split reporter protein to detect and quantify beta-1,6-branched beta-1,3-glucan and beta-1,3-glucan. When the target glucan is present in a sample, fusion proteins that bind to it reconstitute an active reporter protein, and the glucan is quantified by measuring that activity.

Potential applications include:

  • Diagnostic kits for fungal infections (currently at the basic research stage)
  • Measuring beta-glucan content and evaluating the quality of supplements, including King Agaricus KA21
  • Research on how beta-glucans act in the body

Securing patents in Japan, the U.S. and China gives us a foundation for using this technology in research and product quality evaluation in each country. The KA21 trademark is also registered in Japan, China, the EU and Taiwan, and we will continue to share the research and quality behind King Agaricus KA21 with partners around the world.

About King Agaricus KA21

King Agaricus KA21 is grown from our exclusive KA21 strain, cultivated outdoors under natural sunlight in Brazil, the native home of Agaricus (Agaricus blazei / brasiliensis / subrufescens). Compared with indoor-grown Agaricus, it contains higher levels of vitamin D and other nutrients (Japan Food Research Laboratories), and its antioxidant activity has been reported to be more than five times higher (International Journal of Medicinal Mushrooms, 2019; 21(3): 31–43).

Press release (English): https://en.atpress.com/news/644706